1. Introduction {#sec1-pharmacy-04-00014}
===============

Individuals lacking medical insurance are disproportionately likely to suffer from negative health outcomes and barriers to health services than individuals with private or public insurance plans \[[@B1-pharmacy-04-00014],[@B2-pharmacy-04-00014],[@B3-pharmacy-04-00014],[@B4-pharmacy-04-00014],[@B5-pharmacy-04-00014],[@B6-pharmacy-04-00014]\]. Prescription medications can offer a powerful first line of defense against conditions that commonly lead to costly in-patient hospital admissions, such as infections, heart disease and hypertension. However, despite their ability to ameliorate both chronic and acute illnesses, the high-cost of medications often serves as a barrier to access for uninsured individuals \[[@B7-pharmacy-04-00014],[@B8-pharmacy-04-00014],[@B9-pharmacy-04-00014],[@B10-pharmacy-04-00014]\]. Low-cost generic drug programs (LCGPs) offered by major chain pharmacies improve both the affordability and accessibility of medications that may be used to treat many common acute and chronic conditions \[[@B11-pharmacy-04-00014],[@B12-pharmacy-04-00014]\].

LCGPs first appeared in the United States (U.S.) in mid-2006 with Kmart providing 90 days of certain generics for \$15 and was shortly followed by Wal-Mart's \$4 program \[[@B13-pharmacy-04-00014]\]. Since then, generic discount programs are now in place at almost all major pharmacy chains including 8 of the top 10 largest chain pharmacies in the nation and include one-third of the top 100 generics used by Americans by volume \[[@B11-pharmacy-04-00014],[@B13-pharmacy-04-00014],[@B14-pharmacy-04-00014]\]. These programs include a wide variety of medication categories---cardiovascular, antibiotics, asthma, analgesics, anti-diabetes, mental health, men's health, and women's health, among others \[[@B15-pharmacy-04-00014],[@B16-pharmacy-04-00014],[@B17-pharmacy-04-00014]\].

Poor and uninsured individuals arguably have the most to gain from the increased affordability and accessibility offered by LCGPs. Despite the tremendous impact that LCGPs may have on the uninsured population in the U.S., there is a relative dearth of literature assessing the prevalence of LCGP use in a nationally representative uninsured population. In 2008, over 70 million Americans were estimated to have used an LCGP to obtain a prescription medication---a figure that has likely expanded as the number and popularity of these programs has increased \[[@B13-pharmacy-04-00014],[@B17-pharmacy-04-00014],[@B18-pharmacy-04-00014]\]. In this 2008 self-reported survey, one-third of adults and one-quarter of children without insurance coverage reported using these programs \[[@B18-pharmacy-04-00014]\]. However, given that self-reported surveys are particularly prone to recall and selection bias it is difficult to ascertain whether these estimates accurately represent LCGP use in the uninsured population.

Few studies have assessed the demographic and clinical characteristics of LCGP users and non-users \[[@B19-pharmacy-04-00014],[@B20-pharmacy-04-00014]\] and none to our knowledge have assessed LCGP use specifically in an uninsured population. Understanding the factors that influence which individuals currently utilize these programs is a crucial first-step in increasing use amongst patients that have the most to gain from LCGPs. This study had four objectives: (1) Assess the prevalence of LCGP use in a nationally representative uninsured population; (2) Compare demographic and clinical characteristics of LCGP users and non-users; (3) Determine significant predictors of LCGP use; and (4) Analyze trends in LCGP use amongst uninsured individuals from 2007--2012.

2. Materials and Methods {#sec2-pharmacy-04-00014}
========================

2.1. Data Source {#sec2dot1-pharmacy-04-00014}
----------------

This study utilized public use data from the Medical Expenditure Panel Survey (MEPS) for the years 2007--2012. MEPS is a nationally representative survey of civilian, non-institutionalized individuals in the U.S. and includes information on demographics, healthcare utilization, medical conditions, and prescription medication use. MEPS uses an overlapping panel design with a new cohort ("panel") added each year and participating in the survey for up to two years. Data are collected in five rounds throughout a panel's two years of participation. Survey sampling and response weights are included so that population estimates may be obtained.

2.2. Study Subjects and Design {#sec2dot2-pharmacy-04-00014}
------------------------------

A cross-sectional study design was used to compare differences between LCGP users and non-users. Rates of LCGP use from 2007--2012 were quantified to assess trends in the proportions of LCGP fills and LCGP users over these years. These years were chosen because 2007 was the first full year in which LCGPs were available and 2012 is the most recent year of data available from MEPS. Inclusion in the study cohort required that individuals lack medical and pharmacy health insurance for both years of their MEPS panel, had no third party payers in the MEPS pharmacy component, participated in all five rounds of data collection, and reported using at least one prescription medication during their two-year panel period. The final sample was representative of those who are "long-term uninsured" (*i.e*., ≥2 years) who have filled a prescription.

2.3. Use of Low-Cost Generic Programs {#sec2dot3-pharmacy-04-00014}
-------------------------------------

MEPS captures medication fills at the pharmacy level; thus effectively capturing all medication fills paid by cash. Survey participants are first asked in-person about all medications which are have been filled. Surveyors obtain pharmacy information from prescription bottles and receive permission to contact the pharmacies for more information. Once permission is granted, details regarding each fill for each medication are extracted including name, NDC number, and the amounts paid by the customer or any third parties.

Four stipulations were used to define LCGP use: (1) The total cost of the drug was paid out of pocket; (2) The cost of the drug exactly matched the cost of an LCGP drug as reported by pharmacies; (3) The medication was listed on an LCGP formulary from a major chain pharmacy from 2007--2012; and (4) Oral medication fills were dispensed for 30 or 90 day supplies of medications, with the exception of anti-infectives, contraceptives, and steroids which were allowed to vary given differential dosing intervals for these classes. LCGP use was coded at the person level as a binary dependent variable for any use during the study period and at the medication level for each medication fill. Pharmaceutical utilization was determined for medications available from LCGPs based on Multum Lexicon classifications (Cerner Multum™, Denver, CO, USA), which is included in the MEPS pharmacy files for each medication.

2.4. Subject Characteristics {#sec2dot4-pharmacy-04-00014}
----------------------------

Cohort demographics and characteristics of interest included age, race, gender, family income level, number of prescriptions filled. For comparison, the cohort was divided by age categories: 0--17, 18--34, 35--54, 55--64, and 65+ years of age. Family income level was based on MEPS classifications of income levels which are stratified as a percentage of the Federal Poverty Level (FPL): \<100%, 100%--125%, 126%--200%, 201%--400%, and \>400% of the FPL. Residence within a metropolitan statistical area (MSA) was recorded as a binary variable and region was categorized by U.S. Census regions. Race was divided between Whites, Hispanics, African-Americans, Asians, and others. Age, family income, region, MSA and insurance type were all assessed at the last round of data collection. A Charlson Comorbidity Index (CCI) score was calculated for each individual based on the algorithm by Quan *et al.* \[[@B19-pharmacy-04-00014]\].

2.5. Data Analysis {#sec2dot5-pharmacy-04-00014}
------------------

The proportions of LCGP uses and users were tracked from 2007 to 2012. These proportions were compared to overall pharmaceutical utilization for users and non-users over the same time period. Comparisons were conducted for cohort characteristics of interest between users and non-users using chi-square or *t*-tests. Multivariable logistic regression was used to identify factors associated with LCGP use. Adjusted odds ratios (AOR) and 95% confidence intervals were reported. All data analyses were conducted using SAS 9.4 \[[@B21-pharmacy-04-00014]\] (SAS Institute, Cary, NC, USA) implementing SAS procedures (SURVEYMEANS, SURVEYFREQ, and SURVEYLOGISTIC) that take into account the complex survey design of MEPS and use the longitudinal survey weights supplied by MEPS to calculate population estimates over the two-year period. This manuscript was drafted in accordance with STROBE guidelines for reporting observational studies.

3. Results {#sec3-pharmacy-04-00014}
==========

3.1. Cohort Comparison {#sec3dot1-pharmacy-04-00014}
----------------------

Over the years 2007--2012 a total of 2535 uninsured individuals met all inclusion criteria. Applying MEPS person weights, this population represents 8,327,690 uninsured individuals annually who filled a prescription medication---representing approximately one fourth of the U.S. uninsured population prior to the implementation of the Affordable Care Act. Of this population, 39.9% (*N* = 3,321,071) were classified as LCGP users, having filled at least one prescription through an LCGP during their two-year panel period.

Demographic and clinical comparisons between users and non-users are presented in [Table 1](#pharmacy-04-00014-t001){ref-type="table"}. Significant differences between LCGP users and non-users existed in terms of age, sex, MEPS panel, number of medications filled, and number of unique medications used. LCGP users were significantly more likely to be aged 55 or greater than LCGP non-users (19.1% *vs.* 10.4%). Additionally, a significantly greater proportion of LCGP users were female than non-users (55.6% *vs.* 44.7%). In terms of the number of medications used, LCGP users filled significantly more unique prescriptions and had more total medication fills than non-users.

3.2. Predictors of LCGP Use {#sec3dot2-pharmacy-04-00014}
---------------------------

The full multivariable logistic regression model with adjusted odds ratios and 95% confidence intervals is presented in [Table 2](#pharmacy-04-00014-t002){ref-type="table"}. Significant predictors of LCGP use included MEPS panel number and number of unique medications used. Participants in Panels 13--16---taking place from 2008--2012---had greater than double the odds of using an LCGP than individuals in panel 12 (2007--2008). The panel with the greatest odds of using LCGPs was observed to be panel 15 (2010--2011) with individuals in this panel being greater than four times more likely to use an LCGP than those in panel 12 (AOR: 4.02 (95% CI: 2.75--5.87)). Additionally, each unique medication used increased the odds of LCGP use by 43% (AOR: 1.43 (95% CI: 1.27--1.62)).

3.3. Medication Use {#sec3dot3-pharmacy-04-00014}
-------------------

From 2007--2012 the study population filled a total of 20,143 prescriptions, with 81.7% of these prescriptions being available through LCGPs. Out of all medications available through LCGPs, only 34.7% were actually purchased through these programs. The majority of LCGP fills were for medications used to treat chronic conditions.

Trends in the use of LCGPs, including the proportions of LCGP fills and LCGP users in each year as well as the total number of prescription fills per person are presented in [Figure 1](#pharmacy-04-00014-f001){ref-type="fig"}. Proportions of both LCGP users and LCGP fills in each year increased significantly from 2007--2012. The proportion of prescriptions available through LCGPs that were obtained through LCGPs more than quadrupled from 11.0% in 2007 to 45.7% in 2012. Over the same time period, the proportion of LCGP users more than doubled from 19.6% in 2007 to 40.7% in 2012. While the proportions of LCGP users and LCGP fills both increased significantly from 2007--2012, overall pharmaceutical utilization remained relatively constant with approximately 4.8 prescription fills per person per year.

4. Discussion {#sec4-pharmacy-04-00014}
=============

Individuals living for long periods of time without insurance have the most to gain from the affordable medications offered by LCGPs---especially so for those also suffering from chronic illness or living below the poverty line. Results of this study indicate that the increasing use of LCGPs in the uninsured population is not due to increasing pharmaceutical utilization but rather due to increasing popularity and knowledge of these programs. However, despite the dramatic increase in LCGP use amongst the uninsured, it is disconcerting that fewer than 40% of uninsured individuals in the U.S. who use prescription medications are LCGP users. These numbers are comparable to insured adults and lower than elderly adults with Medicare \[[@B20-pharmacy-04-00014]\]. Even when only considering individuals who filled at least one prescription available through LCGPs less than half actually filled that medication through an LCGP.

Uninsured individuals who are living below the federal poverty threshold are disproportionately likely to experience cost of prescription drugs as an impediment to medication access. One would hope that individuals living below the federal poverty level would use LCGPs at a greater rate than individuals better off financially. However, no significant differences were observed regarding the income distribution of LCGP users and non-users and income level was not a significant predictor of LCGP use. Taken together these results indicate that income and specifically poverty are not significant drivers of LCGP utilization.

The self-administered questionnaire in the MEPS household component includes questions regarding whether or not the participant experienced delays in getting necessary prescription medications, and if so, what the cause of the delay was. Given the widespread availability and relative affordability of LCGPs, one might expect that LCGP users would be less likely to experience delays in obtaining necessary medications. Our study found that there is not a significant difference between the number of LCGP users and non-users experiencing delays in obtaining prescription medications; nor do delays in obtaining medications make individuals significantly more or less likely to use LCGPs. Additionally, only 53.5% of individuals who reported cost of medication as the reason for a delay in obtaining medication were classified as LCGP users. Both of these results imply that LCGPs are not adequately being used to prevent delays in obtaining medication, particularly where cost is a prohibitive factor.

Many state and community public health service organizations supply prescription savings cards to uninsured individuals or include outreach programs to supply medications to the needy. These outreach services are a tacit reflection that public health entities understand the benefits of alleviating cost of medications as a barrier to medication access. In addition to these discount cards, public health entities should also actively promote the use of LCGPs and attempt to improve health literacy regarding the comparative efficacy of generic pharmaceutical products. Since many public health organizations already maintain online instructions regarding how to obtain prescription drug assistance, they can also include information about the widespread availability of LCGPs at little to no cost for the organization. Furthermore, prescribers as well as major chain pharmacies should take more of an active role in encouraging the use of LCGPs to treat common chronic and acute illnesses. These programs are being widely used by the rest of the population \[[@B20-pharmacy-04-00014],[@B22-pharmacy-04-00014]\] and the implications of their use have been discussed elsewhere \[[@B11-pharmacy-04-00014]\].

Given the recent expansion of Medicaid under the Affordable Care Act, many of the uninsured individuals included in this study will now be eligible for Medicaid benefits. Although these individuals will now receive prescription drug benefits through Medicaid plans, it is still vitally important to encourage LCGP use in this newly insured population. Previous research has demonstrated that individuals who are uninsured for long periods and subsequently gain insurance will dramatically increase their healthcare utilization and spending once they become insured \[[@B23-pharmacy-04-00014],[@B24-pharmacy-04-00014],[@B25-pharmacy-04-00014]\]. Newly insured individuals under the Affordable Care Act should be encouraged to use LCGPs to decrease the barrier to effective pharmaceutical intervention where cost may still be a limitation even with insurance. This also has the potential to be cost saving for state and federal payers by offsetting the costs of prescription medications as well as decreasing clinical sequelae of conditions which the medications are meant to treat. Also, given the ongoing challenges to the Affordable Care Act, if it were to be totally dismantled, it would be very beneficial for the newly uninsured population to understand that affordable medications are available even without insurance coverage.

Our study is subject to some limitations. It may remain possible that not all medication use is recorded if all pharmacies used were not surveyed. Our study definition of LCGP use may allow for overestimation of use if only pricing is considered. However, this effect is mitigated by requiring specific quantities supplied for oral medications. Our algorithm passed face validity by not detecting medications that are not on LCGP formularies (e.g., benzodiazepines and narcotics) and also included estimates of generic use close to other estimates using surrogate markers of medication use (e.g., 10% of warfarin fills) \[[@B20-pharmacy-04-00014],[@B26-pharmacy-04-00014]\]. We included a population representative of those who are uninsured for at least two continuous years and that have filled a prescription medication. Given the data source, we cannot verify the presence of unfilled medications in the population or account for those included in MEPS that did not report at least one medication fill. Finally, it is possible that some individuals exclusively use pharmacies in which LCGPs are not available and thus this population was never eligible for inclusion in the LCGP user cohort.

5. Conclusions {#sec5-pharmacy-04-00014}
==============

A significant proportion of individuals who were uninsured for two consecutive years from 2007--2012 used an LCGP during this period. Furthermore, the proportion of LCGP users and the proportions of LCGP fills out of all medications available through LCGPs both increased significantly from 2007--2012. Despite the tremendous gains in the rate of LCGP use, certain subgroups including individuals living below the poverty threshold and those experiencing delays in obtaining necessary medications could stand to benefit from greater use of these programs. State and community public health services should work alongside prescribers and major pharmacy chains to encourage greater use of LCGPs among the uninsured population.
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###### 

Demographic characteristics of study cohort.

                                              LCGP Users   Non-Users                                                               
  ------------------------------------------- ------------ ----------------- ----------- -------------- ------- ------ ----------- ------
  *Overall Sample: N = 2535*                                                                                                       
                                              1023         40.4              3,321,071   39.9           1512    59.6   5,006,619   60.1
  *Age \**                                                                                                                         
  0--17                                       55           5.4               197,217     5.9            130     8.6    468,222     9.4
  18--34                                      308          30.1              1,097,996   33.1           597     39.5   2,060,812   41.2
  35--54                                      465          45.5              1,461,488   44             637     42.1   1,955,761   39.1
  55--64                                      180          17.6              531,079     16.0           144     9.5    509,644     10.2
  65+                                         15           1.5               33,290      1.0            4       0.3    12,180      0.2
  *Sex \**                                                                                                                         
  Male                                        413          40.4              1,473,855   44.4           753     49.8   2,766,344   55.3
  Female                                      610          59.6              1,847,216   55.6           759     50.2   2,240,275   44.7
  *Race*                                                                                                                           
  White                                       333          32.6              1,762,453   53.1           485     32.1   2,589,120   51.7
  Hispanic                                    441          43.1              919,879     27.7           668     44.2   1,468,093   29.3
  Black                                       187          18.3              429,532     12.9           252     16.7   659,446     13.2
  Asian                                       38           3.7               118,957     3.6            59      3.9    157,624     3.1
  Other                                       24           2.3               90,249      2.7            48      3.6    132,337     2.6
  *Region*                                                                                                                         
  Northeast                                   70           6.8               270,591     8.1            153     10.1   568,708     11.4
  Midwest                                     161          15.7              598,921     18.0           224     14.8   840,617     16.8
  South                                       540          52.8              1,614,540   48.6           726     48     2,375,859   47.5
  West                                        252          24.6              837,018     25.2           409     27.1   1,221,435   24.4
  *Income Category*                                                                                                                
  \<100% of FPL                               305          29.8              930,090     28.0           461     30.5   1,322,446   26.4
  100% to 125% of FPL                         86           8.4               230,157     6.9            151     10     400,395     8.0
  125% to 200% of FPL                         252          24.6              728,102     21.9           365     24.1   1,117,602   22.3
  200% to 400% of FPL                         274          26.8              900,861     27.1           387     25.6   1,396,285   27.9
  \>400% of FPL                               106          10.4              531,861     16.0           148     9.8    769,891     15.4
  *MSA*                                                                                                                            
  Rural                                       153          15                587,178     17.7           227     15     885,641     17.7
  Urban                                       870          85                2,733,892   82.3           1,285   85     4,120,978   82.3
  *Marital Status*                                                                                                                 
  Not Married                                 563          55                2,023,346   60.9           909     60.1   3,210,180   64.1
  Married                                     460          45                1,297,725   39.1           603     39.9   1,796,439   35.9
  *Employment*                                                                                                                     
  Unemployed                                  366          35.8              1,144,601   34.5           547     36.2   1,680,822   33.6
  Employed                                    657          64.2              2,176,469   65.5           965     63.8   3,325,797   66.4
  *Education*                                                                                                                      
  Less than High School                       345          33.7              824,719     24.8           520     34.4   1,330,469   26.6
  High School or Equivalent                   481          47                1,721,585   51.8           668     44.2   2,402,929   48.0
  Some College                                197          19.3              774,767     23.3           324     21.4   1,273,222   25.4
  *MEPS Panel (years) \**                                                                                                          
  12 (2007--2008)                             109          10.7              469,931     14.1           320     21.2   1,401,201   28
  13 (2008--2009)                             243          23.8              773,787     23.3           385     25.5   1,062,261   21.2
  14 (2009--2010)                             199          19.5              614,551     18.5           292     19.3   967,636     19.3
  15 (2010--2011)                             210          20.5              743,519     22.4           208     13.8   707,594     14.1
  16 (2011--2012)                             262          25.6              719,283     21.7           307     20.3   867,927     17.3
  *Delays In Getting Necessary Medications*                                                                                        
  No Delays                                   919          89.8              2,918,531   87.9           1421    94     4,638,638   92.7
  Delays                                      104          10.2              402,539     12.1           91      6      367,981     7.3
  *CCI \**                                                                                                                         
  0--1                                        856          83.7              2,884,043   86.8           1425    94.2   4,736,873   94.6
  2--4                                        160          15.6              424,906     12.8           65      4.3    214,697     4.3
  5+                                          5            0.5               9106        0.3            4       0.3    9640        0.2
  Missing                                     2            0.2               3016        0.1            18      1.2    45,409      0.9
  *Total Number of Medication Fills \**                                                                                            
  Median (IQR)                                5 (2--16)    4.9 (1.7--16.6)   2 (1--4)    1.3 (1--3.5)                              
  *Unique Medications Used \**                                                                                                     
  Median (IQR)                                3 (2--5)     2.1 (1.1--4.2)    1 (1--2)    1 (1--1.8)                                

\* *p* \< 0.001 between group comparison; Percentages not adding to 100% are due to rounding errors; CCI = Charlson Comorbidity Index; IQR = interquartile range; MSA = metropolitan statistical area; LCGP = low cost generic program; FPL = federal poverty limit.
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###### 

Multivariable logistic regression results of predictive characteristics for LCGP use.

  Characteristic                              Adjusted Odds Ratio   95% Wald Confidence Limits   
  ------------------------------------------- --------------------- ---------------------------- -------
  *Age*                                                             Lower                        Upper
   0--17                                      Ref.                  Ref.                         Ref.
   18--34                                     1.12                  0.63                         2.00
   35--54                                     1.20                  0.65                         2.22
   55--64                                     1.50                  0.75                         2.97
   65+                                        4.02                  0.69                         23.25
  *Gender*                                                                                       
   Male                                       Ref.                  Ref.                         Ref.
   Female                                     1.24                  0.99                         1.56
  *Marital Status*                                                                               
   Not Married                                Ref.                  Ref.                         Ref.
   Married                                    1.00                  0.79                         1.27
  *Employment*                                                                                   
   Unemployed                                 Ref.                  Ref.                         Ref.
   Employed                                   0.98                  0.75                         1.28
  *Education*                                                                                    
   Less than High School                      Ref.                  Ref.                         Ref.
   High School or Equivalent                  1.12                  0.85                         1.46
   Some College                               1.08                  0.75                         1.56
  *Income Category*                                                                              
   \<100% of FPL                              Ref.                  Ref.                         Ref.
   100% to 125% of FPL                        0.79                  0.50                         1.24
   125% to 200% of FPL                        0.96                  0.73                         1.28
   200% to 400% of FPL                        1.02                  0.76                         1.37
   \>400% of FPL                              1.05                  0.69                         1.59
  *Race*                                                                                         
   White                                      Ref.                  Ref.                         Ref.
   Hispanic                                   1.18                  0.89                         1.56
   Black                                      0.93                  0.67                         1.30
   Asian                                      1.36                  0.76                         2.44
   Other                                      1.18                  0.63                         2.19
  *MSA*                                                                                          
   Rural                                      Ref.                  Ref.                         Ref.
   Urban                                      1.11                  0.80                         1.53
  *Region*                                                                                       
   Northeast                                  Ref.                  Ref.                         Ref.
   Midwest                                    1.31                  0.88                         1.93
   South                                      1.27                  0.88                         1.83
   West                                       1.16                  0.79                         1.71
  *Panel Number (years of panel)*                                                                
   12 (2007--2008)                            Ref.                  Ref.                         Ref.
   13 (2008--2009)                            2.33                  1.62                         3.36
   14 (2009--2010)                            2.31                  1.63                         3.29
   15 (2010--2011)                            4.02                  2.75                         5.87
   16 (2011--2012)                            2.78                  1.92                         4.01
  *Delays in Getting Necessary Medications*                                                      
   No Delays                                  Ref.                  Ref.                         Ref.
   Delays                                     1.06                  0.71                         1.58
  *CCI*                                                                                          
   0--1                                       Ref.                  Ref.                         Ref.
   2--4                                       1.49                  0.94                         2.37
   5+                                         0.72                  0.16                         3.18
  *Number of Unique Meds*                     1.43                  1.27                         1.62

CCI = Charlson Comorbidity Index; LCGP = low cost generic program; FPL = federal poverty level; MSA = metropolitan statistical area; Ref. = Reference category for variable.
